Skip to main content
Have a personal or library account? Click to login
Strošek In Učinkovitost Zdravljenja Shizofrenije Z Atipičnimi Antipsihotiki V Sloveniji: Raziskava Stroškovne Učinkovitosti / The Cost And Effects Of Atypical Antipsychotic Agents In Patients With Schizophrenia In Slovenia: A Cost Effectiveness Study Cover

Strošek In Učinkovitost Zdravljenja Shizofrenije Z Atipičnimi Antipsihotiki V Sloveniji: Raziskava Stroškovne Učinkovitosti / The Cost And Effects Of Atypical Antipsychotic Agents In Patients With Schizophrenia In Slovenia: A Cost Effectiveness Study

Slovenian Journal of Public Health
Volume 52 (2013): Issue 1 (March 2013)
By: ,   and    
Open Access
|Jan 2013
References

References

  1. 1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (4nd ed.), text revision (DSM-IV-TR). Washington DC: American Psychiatric Association, 2000.
    Search in Google Scholar
  2. 2. Murray CJL, Lopez AD. The global burden of disease. Cambridge: Harvard University Press, 1996.
    Search in Google Scholar
  3. 3. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: The National Comorbidity Survey. Arch Gen Psychiatry 1996; 53: 1022-1031.
    Open DOISearch in Google Scholar
  4. 4. Goldner EM, Hsu L, Waraich P, Somers JM. Prevalence and incidence studies of schizophrenic disorders: a systematic review of the literature. Can J Psychiatry 2002; 47: 833-843.
    Open DOISearch in Google Scholar
  5. 5. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161: 1334-1349.
    Open DOISearch in Google Scholar
  6. 6. Picchioni MM, Murray RM. Schizophrenia. BMJ 2007; 335: 91-95.
    Open DOISearch in Google Scholar
  7. 7. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophr Bull 1995; 21: 567-577.
    Open DOISearch in Google Scholar
  8. 8. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
    Open DOISearch in Google Scholar
  9. 9. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of firstepisode schizophrenia. Am J Psychiatry 2000; 157: 514-520.
    Open DOISearch in Google Scholar
  10. 10. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, Himelhoch S, Fang B, Peterson E, Aquino PR, Keller W. Schizophrenia Patient Outcomes Research Team (PORT): the 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010; 36: 71-93.
    Open DOISearch in Google Scholar
  11. 11. Inštitut za varovanje zdravja Republike Slovenije. Ambulantno predpisovanje zdravil v Sloveniji po ATC Klasifikaciji v letu 2009. Pridobljeno 28.1.2012 s spletne strani: http://www.ivz.si.
    Search in Google Scholar
  12. 12. IMS health. Pridobljeno 30.1.2012 s spletne strani: http://www.IMShealth.com.
    Search in Google Scholar
  13. 13. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 2004; 21: 419-429.
    Search in Google Scholar
  14. 14. Canuso CM, Dirks B, Carothers J, Kosik-Gonzalez C, Bossie CA, Zhu Y, Damaraju CV, Kalali AH, Mahmoud R. Randomized, double-blind, placebo-controlled study of paliperidoneextended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry 2009; 166: 691-701.
    Open DOISearch in Google Scholar
  15. 15. Canuso CM, Bossie CA, Turkoz I, Alphs L. Paliperidone extendedrelease for schizophrenia: effects on symptoms and functioning in acutely ill patients with negative symptoms. Schizophr Res 2009; 113: 56-64.
    Open DOISearch in Google Scholar
  16. 16. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007; 90:147-161.
    Open DOISearch in Google Scholar
  17. 17. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito GG, Marder SR. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-690.
    Open DOISearch in Google Scholar
  18. 18. Kahn RS, Schulz SC, Palazov VD, Reyes EB, Brecher M, Svensson O, Andersson HM, Meulien D. Efficacy and tolerability of once-daily extended release quetiapinefumarate in acute schizophrenia: a randomized, double-blind, placebocontrolled study. J Clin Psychiatry 2007; 68: 832-842.
    Open DOISearch in Google Scholar
  19. 19. Arvanitis LA, Miller BG. Multiple fixed doses of „Seroquel“ (quetiapine) in patients with acute exacerbation of schizophrenia:a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42: 233-246.
    Open DOISearch in Google Scholar
  20. 20. Kane J, Canas F, Kramer M, Ford L, Gassmann-Mayer C, Lim P, Eerdekens M. Treatment of schizophrenia with paliperidoneextended-release tablets: a 6-week placebocontrolled trial. Schizophr Res 2007; 90: 147-161.
    Open DOISearch in Google Scholar
  21. 21. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, HsiaoJK. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) investigators: effectiveness of antipsychotic drugs in patientswith chronic schizophrenia. N Engl J Med 2005; 353: 1209-1223.
    Open DOISearch in Google Scholar
  22. 22. Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J,Caro O, Leadbetter J, Assuncao S. Response and relapse inpatients with schizophrenia treated with olanzapine, risperidone,quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (ICSOHO) study. J Clin Psychiatry 2005; 66: 1021-1030.
    Open DOISearch in Google Scholar
  23. 23. Mullins CD, Obeidat NA, Cuffel BJ, Naradzay J, Loebel AD. Risk of discontinuation of atypical antipsychotic agents in the treatment of schizophrenia. Schizophr Res 2008; 98: 8-15.
    Open DOISearch in Google Scholar
  24. 24. Lieberman JA, Stroup TS, McEvoy JP et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-1023.
    Open DOISearch in Google Scholar
  25. 25. IMS health. Pridobljeno 30.1.2012 s spletne strani: http://www. IMShealth.com.
    Search in Google Scholar
  26. 26. Zavod za zdravstveno zavarovanje Slovenije. Cene storitev v zdravstvu od 1.1. 2012 dalje. Pridobljeno 25.1.2012 s spletne strani: http://www.zzzs.si/zzzs/pao/izvajalci.nsf/o/0C38E1F23D 89C18FC125796F00173041.
    Search in Google Scholar
  27. 27. Zakonodaja Republike Slovenije. Zakon o duševnem zdravju Republike Slovenije. Pridobljeno 20.1.2012 s spletne strani: http:// zakonodaja.gov.si/rpsi/r07/predpis_ZAKO2157.html.
    Search in Google Scholar
  28. 28. Zavod za zdravstveno zavarovanje Republike Slovenije. Recept glasilo, zadnja verzija. Pridobljeno 20. 1. 2012 s spletne strani: http://www.zzzs.si/ZZZS/info/egradiva.nsf/0/2e6416e75fe33f0 5c125796c00492304/$FILE/Bilten%20Recept_%C5%A1t%20 1_20.12.2011.pdf
    Search in Google Scholar
  29. 29. Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. Annals of General Psychiatry 2008; 7: 16.
    Open DOISearch in Google Scholar
  30. 30. Hausmann A, Fleischhacker WW. Differential diagnosis of depressed mood in patients with schizophrenia: a diagnostic algorithm based on a review. Acta Psychiatr Scand 2002; 106: 83-96.
    Open DOISearch in Google Scholar
  31. 31. Premuš A, Mrhar A. Interakcije med zdravili pri bolnikih na kirurškem oddelku Splošne bolnišnice Murska Sobota. Zdrav Var 2010; 49: 189-201.
    Search in Google Scholar
  32. 32. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006; 32: 715-723.
    Open DOISearch in Google Scholar
  33. 33. Obradović M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. Int J Clin Pract 2007; 6: 1979-1988.
    Open DOISearch in Google Scholar
  34. 34. Young W. The therapeutic window for methylprednisolone treatment of acute spinal cord injury: implications for cell injury mechanisms. Res Publ Assoc Res Nerv Ment Dis 1993; 71: 191-206.
    Search in Google Scholar
  35. 35. Vera-Llonch M, Delea TE, Richardson E, Rupnow M, Grogg A, Oster G. Outcomes and costs of risperidone versus olanzapine in patients with chronic schizophrenia or schizoaffective disorders: a Markov model. Value Health 2004; 7: 569-584.
    Open DOISearch in Google Scholar
  36. 36. Boscoe A, Paramore C, Verbalis JG. Cost of illness of hyponatremia in the United States. Cost Eff Resour Alloc 2006; 4: 10.
    Open DOISearch in Google Scholar
DOI: https://doi.org/10.2478/sjph-2013-0004 | Journal eISSN: 1854-2476 | Journal ISSN: 0351-0026
Journal RSS Feed
Language: English, Slovenian
Page range: 27 - 38
Published on: Jan 16, 2013
Published by: National Institute of Public Health, Slovenia
In partnership with: Paradigm Publishing Services
Keywords:
cost-effectiveness ratio,
decision tree,
atypical antipsychotics,
clinical significance
Related subjects:
Medicine,
Clinical medicine,
Hygiene and environmental medicine

© 2013 Matej Štuhec, Demetrij Petrica, Janez Toni, published by National Institute of Public Health, Slovenia
This work is licensed under the Creative Commons License.

Volume 52 (2013): Issue 1 (March 2013)
Previous article
Next article